Sesti, Giorgio

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial

Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,829

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 1,503

Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials

Monami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 243

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

Nauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 233

Insulin Secretion in Metabolically Obese, but Normal Weight, and in Metabolically Healthy but Obese Individuals

Succurro, E., Marini, M. A., Frontoni, S., Hribal, M. L., Andreozzi, F., Lauro, R., Perticone, F., & Sesti, G. (2008) · Obesity

Pancreatic function and diabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 158

One-Hour Postload Hyperglycemia Is a Stronger Predictor of Type 2 Diabetes Than Impaired Fasting Glucose

Fiorentino, T. V., Marini, M. A., Andreozzi, F., Arturi, F., Succurro, E., Perticone, M., Sciacqua, A., Hribal, M. L., Perticone, F., & Sesti, G. (2015) · The Journal of Clinical Endocrinology & Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes

Cited by 138

Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I

Arturi, F., Succurro, E., Procopio, C., Pedace, E., Mannino, G. C., Lugarà, M., Procopio, T., Andreozzi, F., Sciacqua, A., Hribal, M. L., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism

Growth Hormone and Insulin-like Growth FactorsLiver Disease Diagnosis and Treatment

Cited by 103

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism

Andreozzi, F., Raciti, G. A., Nigro, C., Mannino, G. C., Procopio, T., Davalli, A. M., Beguinot, F., Sesti, G., Miele, C., & Folli, F. (2016) · Journal of Translational Medicine

Metabolism, Diabetes, and CancerDiabetes Treatment and Management

Cited by 102

Low plasma insulin-like growth factor-1 levels are associated with reduced insulin sensitivity and increased insulin secretion in nondiabetic subjects

Succurro, E., Andreozzi, F., Marini, M. A., Lauro, R., Hribal, M. L., Perticone, F., & Sesti, G. (2009) · Nutrition Metabolism and Cardiovascular Diseases

Growth Hormone and Insulin-like Growth FactorsPancreatic function and diabetes

Cited by 85

An empirical index of insulin sensitivity from short IVGTT: validation against the minimal model and glucose clamp indices in patients with different clinical characteristics

Tura, A., Sbrignadello, S., Succurro, E., Groop, L., Sesti, G., & Pacini, G. (2010) · Diabetologia

Diabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes

Cited by 71

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial

Aroda, V. R., González-Galvez, G., Grøn, R., Halladin, N., Haluzík, M., Jermendy, G., Kok, A., Őrsy, P., Sabbah, M., Sesti, G., et al. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 68

PCSK9 inhibitor therapy: A systematic review and meta‐analysis of metabolic and cardiovascular outcomes in patients with diabetes

Monami, M., Sesti, G., & Mannucci, E. (2019) · Diabetes, Obesity and Metabolism

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 58

Immune checkpoints inhibitors and hyperglycemia: A meta-analysis of randomized controlled trials

Monami, M., Naletto, L., Nreu, B., Dicembrini, I., Sesti, G., & Mannucci, E. (2020) · Diabetes Research and Clinical Practice

Cancer Immunotherapy and BiomarkersDiabetes and associated disorders

Cited by 12

Sex-specific differences in myocardial glucose metabolic rate in non-diabetic, pre-diabetic and type 2 diabetic subjects

Succurro, E., Vizza, P., Cicone, F., Cassano, V., Massimino, M., Giofrè, F., Fiorentino, T. V., Perticone, M., Sciacqua, A., Guzzi, P. H., et al. (2023) · Cardiovascular Diabetology

Cardiovascular Function and Risk FactorsDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 5